natgillin/translations-raw huggingface dataset:
In another embodiment the present invention provides compounds of formula (I) wherein wherein R2 is arylalkyl or heteroarylalkyl, substituted with C1-3alkyl, hydroxyl, alkoxy, nitrile, heterocycle or ester and wherein R1 and R3 are as specified above. 
Spoj formulom (1) prema zahtjevu 1 naznačen time što R, je arilalkil ili heteroarilalkil, supstituiran s C;salkilom, hidroksilom, alkoksi, nitrilom, heterociklom ili esterom i pri čemu R, i Rs su kao što je gore navedeno.
alkyl; and aryl; or each R7a and R7b taken together with the carbon atom to which they are attached form a 3- to 8-membered optionally substituted cycloalkyl or a 3- to 8-membered optionally substituted heterocyclo; 
R'*i R'" uzeti zajedno s atomom ugljika za koji su pričvršćeni tvore 3- do 8- člani opcionalno supstituirani cikloalkil ili 3- do 8- člani opcionalno supstituirani heterocikl; rje 1,2,1li 3; sje 1,2, ili 3;
is provided with at least three projections (1.1.6) having side flanges, and in that the supporting legs (1.2) comprise each a fixed part and a tilting part, wherein the fixed part is formed as a beam provided with a complementary flange for the connection with a side flange of the projection (1.1.6). 
ima najmanje tri izbočenja (1.1.6) koja imaju bočne prirubnice, te što svaka od nosivih noga (1.2) ima fiksni dio i nagibajući dio, gdje fiksni dio je načinjen kao greda koja ima komplementarnu prirubnicu za povezivanje s bočnom prirubnicom izbočenja (1.1.6).
A compound as claimed in claim 1, wherein R3 is selected from the group consisting of phenyl, benzyl, pyrazolyl, pyridinyl, pyrazinyl and 2-thienyl, wherein this radical can be unsubstituted or mono- or polysubstituted by substituents independently of each other selected from the group consisting of —F, —Cl, —Br, —CN, —CH3, —C2H5, —NH2, —NO2, —SH, —CF3, OH, —OCH3, —OC2H5 and —N(CH3)2, or R3 is selected from the group consisting of -ethyl, -n-propyl, -n-butyl, -vinyl, or -allyl, unsubstituted or mono- or polysubstituted by —OCH3, —OH or —OC2H5, in particular by —OCH3 or —OC2H5. 
Spoj u skladu s jednim od zahtjeva 1 do 8, naznačen time što R3 je odabran iz skupine koju čine fenil, benzil, pirazolil, piridinil, pirazinil i 2-tienil, pri čemu ovaj radikal može biti nesupstituiran ili mono- ili polisupstituiran supstituentima međusobno neovisno odabranim iz skupine koju čine -F, -Cl, -Br, -CN, -CH3, -C2H5, -NH2, -NO2, -SH, -CF3, OH, -OCH3, -OC2H5 i -N(CH3)2, ili R3 je odabran iz skupine koju čine -etil, -n-propil, -n-butil, -vinil, ili -alil, nesupstituiran ili mono- ili polisupstituiran s -OCH3, -OH ili -OC2H5, te naročito s -OCH3 ili -OC2H5.
A method of treating cells or tissues involved in a pathology characterized by dysfunctional neuronal cells caused by misregulation of the expression of the gene associated with the enzyme pantothene kinase, the method comprising administering to the subject an effective amount of a compound of any one of embodiments 1-5. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi kao medikament za liječenje stanica ili tkiva uključenih u patologiju, naznačen time što postoje disfunkcionalne živčane stanice zbog krive regulacije eksprimiranja gena povezanog s enzimom pantotenat-kinazom.
is a group of formula (II) wherein m is an integer from 0 to 2; 
skupina iz formule (II) [image] pri čemu je m cijeli broj od 0 do 2 n cijeli broj od 2 do 5;
where the drain valve is closed and the chamber is filled with an incompressible fluid prior to pressurizing the filter chamber through opening the system valves; 
– gdje je ispusni ventil zatvoren, a komoru se napuni nestlačivim fluidom prije stavljanja filtarske komore pod tlak otvaranjem sustavnih ventila;
According to this embodiment, the lozenge dissolves or disintegrates gradually, thus releasing a controlled dose of the drug for absorption across the buccal mucosa. 
Prema ovoj varijanti, tableta se otapa ili raspada postepeno, i na taj način oslobađa kontroliranu dozu lijeka za apsorpciju preko sluznice usta.
The pharmaceutical composition of Claim 3, wherein the polymorph of Formula I is present in at least about 95% of the total weight. The pharmaceutical composition of Claim 3, wherein the polymorph of Formula I is present in at least about 99% of the total weight. The pharmaceutical composition of any one of Claims 3 to 8, wherein the pharmaceutical composition is in solid dosage form. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u najmanje 95% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u najmanje99% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
The compound of the Formula XIII may then be coupled with a compound of the Formula III as hereinbefore defined using analogous conditions to those described in process (a) or process (e). 
Spojevi prikazani Formulom XIII mogu se tada povezati sa spojem prikazanim Formulom III u skladu sa ranije navedenom definicijom, primjenom uvjeta koji su analogni uvjetima opisanim u postupku (a) ili postupku (6).
After drying, the crystalline compactin (22.9 g) was collected and analyzed by HPLC. 
Nakon sušenja je sakupljen kristalni kompaktin (22.9 g) i analiziran HPLC-om.
or a pharmaceutically acceptable salt thereof. 
ili njegova farmaceutski prihvatljiva sol, stereoizomer, i/ili N-oksid.
The method according to claim 1, characterized in that the WiFi signal alone and/or together with an audiovisual signal in the form of a satellite TV signal and/or terrestrial TV signal and/or cable TV signal is transmitted by means of a transmission medium (110), each of the above-mentioned signals being transmitted within predetermined frequency ranges. 
Metoda prema patentnom zahtjevu 1, pri čemu se Wi-Fi signal sam i/ili zajedno sa TV signalima prenosi pomoću prijenosnog medija (110), gdje se svaki od gore-navedenih signala prenosi unutar prethodno utvrđenih opsega frekvencije.
Equipment for controlling, measuring and communicating a physical quantity of a container containing a fluid under pressure 
OPREMA ZA KONTROLIRANJE, MJERENJE I IZVJEŠTAVANJE FIZIČKE VELIČINE POSUDE KOJA SADRŽI FLUID POD PRITISKOM
a light chain with the amino acid sequence or 
laki lanac sa sekvencom aminokiselina [image] ili [image];12.
A compound represented by formula I: 
Spoj predstavljen formulom I:
Mass spectra were obtained by an alternating scan method to give molecular weight information. 
Spektri mase dobiveni su alzernacijom scan metode kako bi se molekuli dala informacija glede težine.
The method of claim 1, wherein in said hIL-2 mutein, through the substitution at position 20, an aspartic acid is exchanged for an amino acid which is selected from the group consisting of: histidine (hIL-2-D20H), isoleucine (hIL-2-D200, or tyrosine (hIL-2-D20Y). 
pomoću supstitucije na položaju 20 asparaginska kiselina je zamijenjena sa histidinom (hIL-2-D20H), ili sa izoleucinom (hIL-2-D20I), ili sa tirozinom (hIL-2-D20Y), te
This would move any fluid in line 14 back towards or into bottle 20. 
Time će se zaostali fluid u cjevovodu 14 povući natrag ili u bocu 20.
A composition comprising at least one monoclonal antibody or antigen binding fragment thereof of claim 1, in combination with a carrier, excipient or buffer. 
Pripravak, naznačen time, da sadrži barem jedno monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, u kombinaciji s nosačem, ekscipijentom ili puferom.
N-Alkyl-2,3-dihydro-benzo[d]isothiazoles of formula VI can be prepared by methods analogous to those described in the literature e.g. 
N-klorsukcinimid, N-Alkil-2,3-dihydro-benzo[dlizotiazol formule VI koji se može pripraviti metodama analognim onima opisanim u literaturi, Hoffmann, R.W.
In other more specific embodiments, the present invention provides GLA compounds of formula (III), wherein x is 11, and the GLA compounds have the following structure (IV): 
4. GLA spoj u skladu s patentnim zahtjevom 3, naznačen time što je x 11, a GLA spoj ima sljedeću strukturu (IV):
In the embodiment described below, the first communication system 11 is operated according to the GSM-R standard and the second communication system 12 is operated according to the LTE standard. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se s prvim komunikacijskim sustavom (11) radi prema standardu GSM-R, dok se s drugim komunikacijskim sustavom (12) radi prema standardu LTE.
The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. 
Tekući nosač za pripravke pod tlakom može biti halogenirani ugljikovodik ili neki drugi farmaceutski prihvatljiv propelant.
The compound of claim 5 or 6, wherein the second RNA viral polymerase is selected from the group consisting of adenovirus, influenza A, influenza B, parainfluenza, respiratory syncytial, rhinovirus, Junin, Pichinde, Rift Valley Fever, Dengue Fever, measles, Yellow Fever, tacaribe, Venezuelan equine encephalitis, West Nile, and SARS-CoV viral polymerases. 
Spoj za uporabu sukladno zahtjevu 12, pri čemu je virusna RNK polimeraza polimeraza odabrana iz skupine koju čine virusne polimeraze virusa Denga groznice, virusa influence A, virusa influence B, Junin virusa, virusa ospica, parainfluenca virusa, Pichinde virusa, Punta Toro virusa, respiratornog sincicijalnog virusa, rinovirusa, virusa groznice doline Rift, SARS virusa, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i virusa žute groznice
A compound of formula I according to one of claims 1 to 3, wherein R1 represents H or fluorine, R3 represents H or fluorine, R1A, when present, represents H or fluorine and R2A, when present, represents H or fluorine; 
Spoj formule I prema jednom od zahtjeva 1 do 3, naznačen time, da R1 predstavlja H ili fluor, R3 predstavlja H ili fluor, R1Akada je prisutan, predstavlja H ili fluor i R2A kada je prisutan, predstavlja H ili fluor;
Bedding as claimed in claim 8 or 9, characterized in that said fixing means (19) comprise one or more bars (20) overlapping respective of said tails (7, 8) and fixed to the floor of the stable by a plurality of first mechanical fastening elements (21), such as screws, or the like. 
Prostirka prema zahtjevu 7 ili 8, naznačen time da se gore navedeni elementi za pričvršćivanje (19) sastoje od jedne ili više rešetki koje preklapaju navedene krajeve (7,8) 1 pričvršćene su za pod štale s mnoštvom elemenata za pričvršćivanje prve vrste (21) poput vijaka 1li slično.
The above mentioned polyurethane adhesive types from either the company Dynea or Collano are based on diphenylmethane diisocyanate. 
Gore navedene vrste poliuretanskih ljepila bilo od firme Dvanea ili od firme Collano se temelje na difenilmetan diizocijanatu.
A pharmaceutical composition comprising a therapeutically effective amount of a renin inhibitor in combination with an efflux protein inhibitor, said efflux protein inhibitor being present in an amount such that, following administration, the bioavailability of a renin inhibitor is improved by at least 5 %, wherein the renin inhibitor is a δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative, or a pharmaceutically acceptable salt thereof, wherein the efflux protein inhibitor is a MDR1 inhibitor. 
Farmaceutski pripravak, naznačen time, da sadrži terapeutski učinkovitu količinu inhibitora renina u kombinaciji s inhibitorom istjecanja proteina, pri čemu je navedeni inhibitor istjecanja proteina prisutan u količini takvoj da se nakon primjene bioraspoloživost inhibitora renina poboljša najmanje 5%, pri čemu inhibitor renina je derivat amida δ-amino-Y-hidroksi-w-aril-alkanoične kiseline ili je to njegova farmaceutski prihvatljiva sol, te pri čemu inhibitor istjecanja proteina je MDR1 inhibitor.
The locking panel socket as claimed in claim 20, in which the third portion of the linking portion is integral with the second portion of the linking portion. 
Panel utičnica (1) sa zaključavanjem prema zahtjevu 5, naznačena time da je treći dio (46) integralan s drugim dijelom (30).
and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and 
Ri R' su uzeti zajedno sa kontinuiranim vezujućim atomima dušika i ugljika tako da formiraju izborno supstituirani prsten R-2; i
The compound of claim 1 having formula (IX) or a pharmaceutically acceptable salt thereof. 
g (Rp pu N OH (IX) ili njegova farmaceutski prihvatljiva sol; ili
When a compound of the present invention has more than one chiral substituents, it may exist in diastereoisomeric forms. 
Kada spoj prema ovom izumu više kiralnih supstituenata, može postojati u dijastereoizomernim oblicima.
a second step comprising oxidizing one or more carbohydrates on FVIII, wherein sodium periodate is added to the solution in the first step to result in a final concentration of about 400 µM, under conditions comprising a time period of about 10 minutes, a temperature of about 22 °C, the absence of light and with stirring; 
pri čemu je krajnja koncentracija oksidirajućeg agensa u drugom koraku oko 400 µM, i uvjeti sadrže vremenski period od oko 10 minuta, temperaturu od oko 22 °C, odsutnost svjetla i s miješanjem;
is nitro or N(R5)E. is as defined in formula I, E is an amino protecting group or a group of formula -A4-G, wherein 
LI je nitro ili N(RSJE, RS je kao što je definirano u formuli I; E je zaštitna skupina za amino ili skupina formule -A4-G, gdje
it has a decreased sialylation degree with an amount of NeuNAc on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition which is at least 15% lower compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira, i/ili – sadrži najmanje 20% više nabijenih N-glikozidno vezanih ugljikohidratnih lanaca u ukupnim ugljikohidratnim jedinicama ili u najmanje jednom određenom ugljikohidratnom lancu na određenom mjestu glikoziliranja u molekuli proteina kod molekula proteina u navedenom pripravku s molekulom proteina u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
Examples of water-soluble preservatives are sodium bisulfite, sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, timerosal, methylparaben, polyvinyl alcohol, phenylethyl alcohol and the like. 
Primjeri u vodi topljivih konzervansa su natrij bisulfit, natrij bisulfat, natrij tiosulfat, benzalkonij klorid, klorobutanol, tiomersal, metilparaben, polivinil alkohol, feniletil alkohol i slično.
wherein the composition: 
naznačen time, da sastav:
As best shown in FIGS. 5, 9 and 10, each ball screw nut 56,58 includes a ball nut extension 100 and a torque tube 102. 
Kao što se najbolje vidi na slikama 5, 9 i 10, svaka od matica (56), (58) sadrži nastavak (100) i momentnu cijev (102).
The compound according to claim 1 wherein R1, R2, and R3 are hydrogen; 
Spoj u skladu s patentnim zahtjevom 5, naznačen time, da su R1, R2, R3 vodik;
The slurry of claim 1 or 2 wherein the aluminum or aluminum alloy powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 4 to 7 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 11.5-15.5 microns. 
Gusta smjesa iz patentnog zahtjeva 1 ili 3, pri čemu aluminij ili prah aluminijeve slitine obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 4 i 7 mikrometara (mikrona) i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 11.5-15.5 mikrometara.
A taste panel of 62 respondents composed of 50 % of men and 50 % of women, of which 31 % between 18 and 35 years old, 35 % between 36 and 50 years old, and 34 % older than 50 years, were asked to taste cookies with sugar and a cookies with the sugar replacer according to the invention, prepared according to the above mentioned recipe and procedure. 
Testirane su 62 osobe, od toga 50 % muškaraca i 50 % žena, 31 % u dobi od 18 do 35 godina, 35 % u dobi od 36 do 50 godina i 34 % starijih od 50 godina, koje su zamoljene da kušaju i kolač pripravljen sa šećerom i onaj sa zamjenom za šećer, pripravljen prema gore navedenom receptu i postupku.
wherein the PSA is oxidized by incubation with a oxidizing agent to form a terminal aldehyde group at the non-reducing end of the PSA. 
GJ o" A "Nu, pri čemu je PSA oksidiran inkubacijom s oksidirajućim agensom kako bi se formirala
A peptide as claimed in any preceding claim, formulated for enteral administration. 
Peptid za koji se traži zaštita u patentnim zahtjevima 1 ili 2, formuliran za enteralnu primjenu.
The composition of claim 6, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17. 
(iv) signalni region 4-IBB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18;
Compounds of the formula (I) in which R is H can also be purified to very high levels by reacting them with phthalic anhydride to form the phthalimido derivatives which can then be converted back to the compounds in which R is H by the methods previously described. 
Spojevi formule (I) u kojima je RH mogu se također prečistiti do vrlo visokih razina njihovom reakcijom s ftalnim anhidridom tako da se formiraju ftalimido derivati koji se mogu tada prevesti natrag u spojeve u kojima je R* H postupcima koji su opisani ranije.
The compound of Claim 35, wherein L is -NHC(O)- and Y is an optionally substituted phenyl. 
36. Spoj prema zahtjevu 35, naznačen time da L je i Y je opcijski supstituiran fenil.
a plurality of active agent particles comprising crystalline glycopyrrolate, including any pharmaceutically acceptable salts, esters, or solvates thereof, wherein at least 90% of the active agent particle material by volume exhibits an optical diameter of 7 µm or less, said active agent particles are included in the suspension medium at a concentration sufficient to provide a delivered dose of glycopyrrolate of between 15 µg and 80 µg per actuation of the metered dose inhaler; and 
prvu vrstu čestica aktivnog sredstva koje sadrže glikopirolat, uključujući sve njegove farmaceutski prihvatljive soli, estere ili solvate, suspendirane u suspenzijskom mediju u koncentraciji dovoljnoj da se osigura isporučena doza glikopirolata od sve do 15 µg to 80 µg po aktiviranju inhalatora s odmjerenom dozom;
The method of any of Claims 1 to 5, wherein the aqueous acetate or glutamate buffered G-CSF composition provided in step (a) has a volume of from100 ml to 4 I, and more preferably of from 100 ml to 1.5 I. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time, da vodeni acetat ili glutamat puferiranog G-CSF- sastava, koji je pribavljen u koraku (a), ima volumen od 100 ml do 4 [, 1 još bolje od 100 ml do 1,5 L
A method according to any one of claims 1-11, wherein said antimony (III) compounds is added together with antioxidants, radical scavengers, grinding aids, cement performance enhancers or mixtures thereof. A cement additive comprising an antimony (III) compound in admixture with suitable carriers and/or adjuvants. 
Metoda prema bilo kojem od patentnih zahtjeva 1-10, naznačena time da su rečeni spojevi antimona(III) dodani zajedno s antioksidfansima, spojevima za uklanjanje slobodnih radikala, pomoćnih sredstava pri mljevenju, sredstva za poboljšanje cementa ili njihove smjese.
after the filling with a homogenously pressurized fluid of all the cavities of the inner rotor (IR) is achieved, dropping the fluid pressure around the inner rotor (IR) to cause no-return valve of outer hollow cylinder to lock; 
nakon što homogeni fluid pod pritiskom ispuni sve šupljine unutarnjeg rotora (UR), pritisak fluida oko unutarnjeg rotora (UR) opada, izazivajući zatvaranje ventila (32) montiranog na vanjskom cilindru (1);
A compound of formula (II): 
Spoj formule (III): naznačen time, da:
The high-modulus glass fiber composition of claim 2, wherein the range of the weight percentage ratio C4=La2O3/CeO2 is greater than 1. 
Pripravak od fiberglasa visokih svojstava sukladno zahtjevu 2, pri čemu je opseg omjera težinskog postotka C4=La2O3/CeO2 veći od 1.
The entire length of the article is overwrapped with conventional cigarette paper 46. 
Cjela dužina proizvoda je omotana sa konvencionalnim cigaret papirom 46.
An oral cannabinoid dosage form comprising a first composition and a second composition, wherein the first composition comprises a therapeutically-effective amount of trans-(±)-A9-tetrahydrocannabinol in the crystalline form, and the second composition comprises an effective amount of an agent that is adverse to the pharmacological activity of the trans-(±)-A9-tetrahydrocannabinol in the crystalline form, preferably said agent is selected from the group consisting of SR 141716 A, SR 144528, and combinations thereof for use as a medicament. 
Oralni oblik doziranja kanabinoida koji sadrži prvi sastav i drugi sastav, naznačen time da prvi sastav sadrži terapeutski učinkovitu količinu trans-(±)-A9-tetrahidrokanabinola u kristalnom obliku, i da drugi sastav sadrži učinkovitu količinu agensa koji je protudjelotvoran na farmakološku aktivnost trans-(±)-A9-tetrahidrokanabinola u kristalnom obliku, po mogućnosti navedeni agens je odabran od skupine koja se sastoji od SR 141716 A, SR 144528, i njihovih kombinacija za upotrebu kao lijek.
The stabilized etanercept composition of claim 2 wherein the composition elicits long term storage stability as characterized by: 
Stabilizirana kompozicija etanercepta prema patentnom zahtjevu 2, gdje kompozicija dovodi do stabilnosti pri dugotrajnom skladištenju, naznačena:
In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. 
U mekim kapsulama aktivne spojeve se može otopiti ili suspendirati u pogodnim tekućinama, poput masnih ulja, tekućeg parafina ili tekućih polietilen-glikola.
The examples are merely illustrative and to not limit the teaching of this invention and it would be obvious that various modifications or changes in the procedural steps as well as compositions by those skilled in the art without departing from the scope of the invention and shall be consequently encompassed within the ambit and spirit of this approach and scope thereof. 
Primjeri su samo ilustrativni te ne ograničavaju učenja ovog izuma te bi bilo očigledno da različite modifikacije ili promjene u koracima postupka kao i kompozicija od strane vještih stručnjaka bez da se udalje od dosega ovog izuma budu posljedično uključene unutar dosega i duha ovog pristupa i njegova dometa.
Vitamin C deficiency develops when the dietary intake is inadequate. 
Nedostatak vitamina C razvija se kod nedostatnog unosa prehranom.
wherein R1 represents hydrogen or a lower alkyl group; 
R' predstavlja vodik ili skupinu niži alkil;
The system according to claim 13, wherein the hydrogel is a co-polymer of polysulfonate and acrylic acid. 
Sustav prema patentnom zahtjevu 10 dio (c), naznačen time što je hidrogel kopolimer polisulfata i akrilne kiseline.
The use of claims 1 or 2, wherein the medicament is an oral suspension. 
Uporaba patentnih zahtjeva 1-7, naznačena time, da je lijek oralna suspenzija.
By way of example, the thickness s of the corrugated side wall 2 can range from 5 mm to 7 mm, depending upon some parameters, such as the material used, the core stiffness required and the density of the ribs (3, 4). 
Primjerice, debljina s valovite bočne stijenke 2 može se kretati u rasponu od 5 do 7 mm, što ovisi od nekoliko parametara, kao što su: tip korištene sirovine, tražena čvrstoća jezgre te gustoća nabora (3, 4).
The compound of Paragraph 1, wherein R5 is selected from the group consisting of: and wherein: 
4. Spoj prema zahtjevu 1, pri čemu je Rs izabran iz skupine koju čine X s